Circulating biomarkers for early detection and clinical management of colorectal cancer
| Autor: | Guus van Dalum, Veronika Vymetalkova, Antoni Castells, Hege Marie Vedeld, Georg Flügen, Remond J.A. Fijneman, Ellen Heitzer, Emma Tham, Rui P L Neves, Nikolas H. Stoecklein, Saray Duran-Sanchon, Guro Elisabeth Lind, Pavel Vodicka, Meritxell Gironella, Vanesa García-Barberán, María Marcuello |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Colorectal cancer Clinical Biochemistry Early detection Biochemistry Circulating Tumor DNA 03 medical and health sciences 0302 clinical medicine Circulating tumor cell Internal medicine microRNA medicine Biomarkers Tumor Humans Circulating MicroRNA Liquid biopsy Molecular Biology Early Detection of Cancer business.industry Liquid Biopsy Disease Management General Medicine medicine.disease Neoplastic Cells Circulating Prognosis digestive system diseases Circulating biomarkers 030104 developmental biology Cell-free fetal DNA 030220 oncology & carcinogenesis Molecular Medicine business Colorectal Neoplasms |
| Zdroj: | Molecular aspects of medicine. 69 |
| ISSN: | 1872-9452 |
| Popis: | New non-invasive approaches that can complement and improve on current strategies for colorectal cancer (CRC) screening and management are urgently needed. A growing number of publications have documented that components of tumors, which are shed into the circulation, can be detected in the form of liquid biopsies and can be used to detect CRC at early stages, to predict response to certain therapies and to detect CRC recurrence in a minimally invasive way. The analysis of circulating tumor DNA (ctDNA), tumor-derived cells (CTC, circulating tumor cells) or circulating microRNA (miRNA) in blood and other body fluids, have a great potential to improve different aspects of CRC management. The challenge now is to find which types of components, biofluids and detection methods would be the most suitable to be applied in the different steps of CRC detection and treatment. This chapter will provide an up to date review on ctDNA, CTCs and circulating miRNAs as new biomarkers for CRC, either for clinical management or early detection, highlighting their advantages and limitations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect